Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 8, 2016

Biogen Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-19311
33-0112644
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

225 Binney Street, Cambridge, Massachusetts 02142
(Address of principal executive offices; Zip Code)
    
Registrant’s telephone number, including area code: (617) 679-2000
Not Applicable
(Former name or former address, if changed since last report.)
    
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 5.07     Submission of Matters to a Vote of Security Holders

On June 8, 2016, the Company held its Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

1.
Stockholders elected eleven nominees to the Board of Directors to serve for a one-year term extending until the 2017 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:
Nominee
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
Alexander J. Denner
 
174,539,454

 
893,682

 
156,718

 
15,341,806

Caroline D. Dorsa
 
174,480,779

 
948,828

 
160,247

 
15,351,806

Nancy L. Leaming
 
174,714,214

 
715,699

 
159,941

 
15,341,806

Richard C. Mulligan
 
174,278,133

 
1,153,119

 
158,602

 
15,351,806

Robert W. Pangia
 
172,965,385

 
2,465,619

 
158,850

 
15,351,806

Stelios Papadopoulos
 
171,437,694

 
2,916,140

 
1,236,020

 
15,341,806

Brian S. Posner
 
174,610,247

 
819,301

 
160,306

 
15,341,806

Eric K. Rowinsky
 
173,285,332

 
2,144,051

 
160,471

 
15,341,806

George A. Scangos
 
172,548,069

 
2,884,049

 
157,736

 
15,341,806

Lynn Schenk
 
173,190,776

 
2,241,967

 
157,111

 
15,341,806

Stephen A. Sherwin
 
154,451,332

 
20,644,275

 
494,247

 
15,341,806



2.
Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
188,715,983
 
1,983,681
 
231,996
 


3.
Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
170,639,138
 
4,521,474
 
429,242
 
15,341,806








Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Biogen Inc.
By:    _/s/ Steven N. Avruch_____________________
Steven N. Avruch
Chief Corporation Counsel and Assistant Secretary
Date: June 9, 2016